Haleon Pakistan Limited has approved a £3.58 million investment to expand and modernize its Panadol Liquid packaging line, as the company moves to boost capacity and meet rising demand in the consumer healthcare market.
According to a disclosure submitted to the Pakistan Stock Exchange, the investment was approved by the company’s board of directors and will be used to procure advanced packaging machinery, upgrade existing infrastructure, and strengthen quality control systems.
The company said the expansion is aimed at improving operational efficiency while enhancing production capability for Panadol Liquid, one of its key over the counter products in Pakistan.
Haleon Pakistan said the initiative reflects its long-term growth strategy and continued focus on innovation in the consumer healthcare segment.
The disclosure stated that the project will involve modernisation of the existing packaging line, allowing the company to respond more effectively to market demand and maintain product quality standards.
Haleon Pakistan is part of Haleon plc, a global consumer healthcare company formed following the demerger of GSK’s consumer healthcare business. The group’s portfolio includes well-known brands such as Panadol, Centrum, and Sensodyne.
